Breast Cancer

Neil M. Iyengar, MD, highlighted the recent T-DXd and Dato-DXd approvals in breast cancer.

Ten-year data from the phase 3 APHINITY trial will be presented at the 2025 European Society for Medical Oncology Breast Cancer Congress.

Policy changes supporting breastfeeding may address structural barriers and lower overall incidence and racial disparities surrounding TNBC in the US.

Neoadjuvant trastuzumab deruxtecan/THP showed an enhanced safety profile vs the standard-of-care regimen in patients with early-stage breast cancer.

Preliminary results from a phase 1 trial show an objective response rate of 13.3% with avutometinib, abemaciclib, and fulvestrant in CDK4/6 inhibitor–resistant HR+/HER2– metastatic breast cancer.

Utilizing a multidisciplinary breast cancer clinic helped improve time to first appointment and time to first treatment.

IBTR with the 1 mm and 2 mm cutoff found rates found the margin widths were small and not clinically meaningful.

Ninety days of endocrine therapy before surgery could change patient/surgeon preference on concurrent radiation use in those with breast cancer.

The regulatory decision may offer more scheduling flexibility for patients who receive thiotepa for breast or ovarian cancer.

No grade 3/4 treatment-related adverse effects were observed in patients receiving efbemalenograstim alfa for breast cancer in the Guard-02 trial.

Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.